Adamas Pharmaceuticals Inc. buy klostergang

Adamas's ADS-5102 could become the first FDA approved drug for Parkinson's disease

klostergang stimmt am 20.08.2017 der fundamentalen Bewertung mit dem Ergebnis unterbewertet zu.

FDA has given a vote of confidence to ADS-5102 by approving NDA application and granting upcoming PDUFDA date of August 24.
A 3-star ranked Cowen analyst reiterated Buy rating on the stock earlier this week with $45 price target. The analyst expressed confidence in ADS-5102's approval and appreciated the management's preparations for commercialization. Armistice Capital, a well-known institutional investor (with $500 million in AUM) bought 1.14 million shares in June 2017 (5.1% stake). Parkinson's disease is also a hot therapeutic area for M&A as shown by recent $1.1B Neuroderm acquisition, $624 million acquisition of Cynapsus Therapeutics, and $363 million acquisition of Biotie.
The company is well-funded with $145 million in cash reserves at the end of Q2'17. It had $33.7 million in long-term debt. At operating cash burn of $26.6B in H1'17, there is no immediate need to raise capital in next 12 months.